The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Actionable alterations (AA) in gastrointestinal (GI) cancers: Rate of detection and receipt of matched therapies (MT).
 
Megan Greally
Travel, Accommodations, Expenses - Pfizer
 
Yaelle Tuvy
No Relationships to Disclose
 
Brittanie M Millang
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Agios (I); AstraZeneca (I); Bayer (I); BeiGene (I); Berry Genomics (I); Celgene (I); CytomX Therapeutics; Debiopharm Group (I); Debiopharm Group (I); Eisai (I); Exelixis/Ipsen (I); Flatiron Health (I); Genentech/Roche (I); Genoscience Pharma (I); Incyte (I); Janssen; LAM Therapeutics (I); Lilly (I); Loxo; Merck; Minapharma (I); QED Therapeutics (I); RedHill Biopharma (I); Sillajen (I); SOBI; Targovax; Yiviva (I)
Research Funding - AstraZeneca/MedImmune (Inst)
 
Rona Yaeger
Consulting or Advisory Role - Array BioPharma
Research Funding - Array BioPharma; Boehringer Ingelheim; Novartis
Travel, Accommodations, Expenses - Array BioPharma
 
Leonard B. Saltz
Research Funding - Taiho Pharmaceutical
 
Geoffrey Yuyat Ku
Consulting or Advisory Role - Lilly; Merck Sharp & Dohme; Pieris Pharmaceuticals
Research Funding - Arog (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst); Zymeworks
Travel, Accommodations, Expenses - Aduro Biotech; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Sharp & Dohme; Pieris Pharmaceuticals